{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:55:58Z","timestamp":1777953358638,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X020258\/1"],"award-info":[{"award-number":["MR\/X020258\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014895","name":"Open Philanthropy Project","doi-asserted-by":"publisher","award":["GV673604959"],"award-info":[{"award-number":["GV673604959"]}],"id":[{"id":"10.13039\/100014895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The malaria vaccine R21\/Matrix-M is recommended for young children in malaria-endemic regions. However, the small vaccine-eligible population and waning vaccine efficacy mean that routine vaccination is unlikely to prevent severe cases in older children who experience significant malaria burden. As R21\/Matrix-M vaccination expands, targeting older age groups may be warranted, depending on funding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using a stochastic, individual-based\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      malaria transmission model, we estimate the impact of (1) one-off catch-up campaigns with R21\/Matrix-M to previously unvaccinated age groups between age 6 months and 14 years, and\/or (2) extra boosters at 2, 5, and\/or 10 years after the primary series in low, moderate, and high transmission settings. We assume that vaccine immunogenicity in older children is equivalent to that of the standard target age group, though clinical trials have shown lower immunogenicity in older children.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Catch-up campaigns in moderate-to-high transmission settings targeting younger children averted the most uncomplicated cases per 1000 additional doses (358 (95% credible interval (CI) 113\u2013570) in children aged 6 months\u20132 years at 45%\n                      <jats:italic>Pf<\/jats:italic>\n                      PR\n                      <jats:sub>2-10<\/jats:sub>\n                      ), compared with targeting older children. In low transmission settings, the impact was similar across age groups, with a slightly higher impact when targeting school-aged children (373 (95% CrI 240\u2013518) in children aged 5\u20139 years at 5%\n                      <jats:italic>Pf<\/jats:italic>\n                      PR\n                      <jats:sub>2-10<\/jats:sub>\n                      ). Across extra booster strategies, an extra booster 10 years post-\u00a0primary series averted the most severe cases per 1000 additional doses at low transmission (12 (95% CrI 6\u201318) at 5%\n                      <jats:italic>Pf<\/jats:italic>\n                      PR\n                      <jats:sub>2-10<\/jats:sub>\n                      ), but the least at high transmission (\u2212\u20094 (95% CrI\u2009\u2212\u200911\u20133) at 45%\n                      <jats:italic>Pf<\/jats:italic>\n                      PR\n                      <jats:sub>2-10<\/jats:sub>\n                      ).\n                    <\/jats:p>\n                    <jats:p>\n                      Expanding the vaccine-eligible population in areas of moderate-to-high transmission often had higher incremental efficiency than routine age-based vaccination at low transmission.\u00a0For example, an extra booster\u00a05 years\u00a0post-primary series averted 835 (95% CrI 605-1274) clinical cases per 1000 additional\u00a0doses in a 45%\n                      <jats:italic>Pf<\/jats:italic>\n                      PR\n                      <jats:sub>2-10<\/jats:sub>\n                      \u00a0perennial setting versus 247 (95% CrI 177-345)\u00a0clinical cases per 1000 doses\u00a0with routine vaccination in a\u00a05%\u00a0\n                      <jats:italic>Pf<\/jats:italic>\n                      PR\n                      <jats:sub>2-10<\/jats:sub>\n                      \u00a0perennial setting. Sensitivity analyses assuming lower immunogenicity in older children modestly reduced the per-dose impact, but overall conclusions remained unchanged.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Catch-up campaigns or extra booster doses of R21\/Matrix-M can provide benefits beyond routine administration, with the per-additional-dose value approaching that of routine vaccination, but this varies by transmission and seasonality setting. Further empirical studies, particularly on vaccine efficacy in older children, are warranted to inform policy guidance for malaria vaccination implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04822-y","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:06:50Z","timestamp":1774433210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Public health impact of catch-up vaccination or additional booster doses with pre-erythrocytic malaria vaccine R21\/Matrix-M: a modelling study"],"prefix":"10.1186","volume":"24","author":[{"given":"Kelly","family":"McCain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary M.","family":"Topazian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Challenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Okell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Winskill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azra C.","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"4822_CR1","unstructured":"World Health Organization. World malaria report 2024: addressing inequity in the global malaria response. 2024. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024"},{"key":"4822_CR2","unstructured":"SAGE\/MPAG Working Group on Malaria Vaccines. Full evidence report on the R21\/Matrix-M malaria vaccine. 2023."},{"key":"4822_CR3","volume-title":"Full evidence report on the RTS, S\/AS01 malaria vaccine","author":"Malaria Vaccine Implementation Programme (MVIP) Programme Advisory Group (PAG)","year":"2021","unstructured":"Malaria Vaccine Implementation Programme (MVIP) Programme Advisory Group (PAG). Full evidence report on the RTS, S\/AS01 malaria vaccine. Geneva: WHO; 2021."},{"issue":"7","key":"4822_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"RTS,S Clinical Trials Partnership","year":"2014","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11(7):e1001685. https:\/\/doi.org\/10.1371\/journal.pmed.1001685.","journal-title":"PLoS Med"},{"issue":"9988","key":"4822_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(15)60721-8.","journal-title":"Lancet"},{"issue":"1","key":"4822_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1473-3099(23)00368-7","volume":"24","author":"A Dicko","year":"2024","unstructured":"Dicko A, Ouedraogo JB, Zongo I, et al. Seasonal vaccination with RTS,S\/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. Lancet Infect Dis. 2024;24(1):75\u201386. https:\/\/doi.org\/10.1016\/S1473-3099(23)00368-7.","journal-title":"Lancet Infect Dis"},{"key":"4822_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02511-4","author":"MS Datoo","year":"2024","unstructured":"Datoo MS, Dicko A, Tinto H, et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet. 2024. https:\/\/doi.org\/10.1016\/S0140-6736(23)02511-4.","journal-title":"Lancet"},{"key":"4822_CR8","unstructured":"World Health Organization. Malaria vaccine dashboard. 2025. https:\/\/app.powerbi.com\/view?r=eyJrIjoiZmZjN2RkOGYtYzM4NS00MWYxLThhYmMtYzg3YjMwYjU2ZDA4IiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9. Accessed 13 Feb 2026."},{"issue":"20","key":"4822_CR9","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","volume":"365","author":"ST Agnandji","year":"2011","unstructured":"RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, et al. First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children. N Engl J Med. 2011;365(20):1863\u201375. https:\/\/doi.org\/10.1056\/NEJMoa1102287.","journal-title":"N Engl J Med"},{"issue":"1","key":"4822_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04098-6","volume":"21","author":"B Greenwood","year":"2022","unstructured":"Greenwood B, Zongo I, Dicko A, Chandramohan D, Snow RW, Ockenhouse C. Resurgent and delayed malaria. Malar J. 2022;21(1):77. https:\/\/doi.org\/10.1186\/s12936-022-04098-6.","journal-title":"Malar J"},{"issue":"26","key":"4822_CR11","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu A, Fegan G, Wambua J, et al. Seven-year efficacy of RTS,S\/AS01 malaria vaccine among young African children. N Engl J Med. 2016;374(26):2519\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1515257.","journal-title":"N Engl J Med"},{"issue":"8","key":"4822_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1473-3099(19)30300-7","volume":"19","author":"H Tinto","year":"2019","unstructured":"Tinto H, Otieno W, Gesase S, et al. Long-term incidence of severe malaria following RTS,S\/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Lancet Infect Dis. 2019;19(8):821\u201332. https:\/\/doi.org\/10.1016\/S1473-3099(19)30300-7.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"4822_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004383","volume":"4","author":"AC Ghani","year":"2009","unstructured":"Ghani AC, Sutherland CJ, Riley EM, et al. Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS ONE. 2009;4(2):e4383. https:\/\/doi.org\/10.1371\/journal.pone.0004383.","journal-title":"PLoS ONE"},{"issue":"9","key":"4822_CR14","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/infdis\/jiac322","volume":"226","author":"GJ Bell","year":"2022","unstructured":"Bell GJ, Goel V, Essone P, et al. Malaria transmission intensity likely modifies RTS, S\/AS01 efficacy due to a rebound effect in Ghana, Malawi, and Gabon. J Infect Dis. 2022;226(9):1646\u201356. https:\/\/doi.org\/10.1093\/infdis\/jiac322.","journal-title":"J Infect Dis"},{"key":"4822_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4136","volume":"5","author":"JT Griffin","year":"2014","unstructured":"Griffin JT, Ferguson NM, Ghani AC. Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat Commun. 2014;5:3136. https:\/\/doi.org\/10.1038\/ncomms4136.","journal-title":"Nat Commun"},{"issue":"12","key":"4822_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025510","volume":"7","author":"T Bousema","year":"2017","unstructured":"Bousema T, Drakeley C. Determinants of malaria transmission at the population level. Cold Spring Harb Perspect Med. 2017;7(12):a025510. https:\/\/doi.org\/10.1101\/cshperspect.a025510.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"4822_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2295-4","volume":"17","author":"JE Coalson","year":"2018","unstructured":"Coalson JE, Cohee LM, Buchwald AG, et al. Simulation models predict that school-age children are responsible for most human-to-mosquito Plasmodium falciparum transmission in southern Malawi. Malar J. 2018;17(1):147. https:\/\/doi.org\/10.1186\/s12936-018-2295-4.","journal-title":"Malar J"},{"issue":"1","key":"4822_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-2110-7","volume":"16","author":"MK Mwandagalirwa","year":"2017","unstructured":"Mwandagalirwa MK, Levitz L, Thwai KL, et al. Individual and household characteristics of persons with Plasmodium falciparum malaria in sites with varying endemicities in Kinshasa Province, Democratic Republic of the Congo. Malar J. 2017;16(1):456. https:\/\/doi.org\/10.1186\/s12936-017-2110-7.","journal-title":"Malar J"},{"issue":"7","key":"4822_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134061","volume":"10","author":"JA Walldorf","year":"2015","unstructured":"Walldorf JA, Cohee LM, Coalson JE, et al. School-age children are a reservoir of malaria infection in Malawi. PLoS ONE. 2015;10(7):e0134061. https:\/\/doi.org\/10.1371\/journal.pone.0134061.","journal-title":"PLoS ONE"},{"issue":"2","key":"4822_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008988","volume":"5","author":"I Carneiro","year":"2010","unstructured":"Carneiro I, Roca-Feltrer A, Griffin JT, et al. Age-patterns of malaria vary with severity, transmission intensity and seasonality in Sub-Saharan Africa: a systematic review and pooled analysis. PLoS ONE. 2010;5(2):e8988. https:\/\/doi.org\/10.1371\/journal.pone.0008988.","journal-title":"PLoS ONE"},{"issue":"1","key":"4822_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001157","volume":"9","author":"T Smith","year":"2012","unstructured":"Smith T, Ross A, Maire N, et al. Ensemble Modeling of the Likely Public Health Impact of a Pre-Erythrocytic Malaria Vaccine. PLoS Med. 2012;9(1):e1001157. https:\/\/doi.org\/10.1371\/journal.pmed.1001157.","journal-title":"PLoS Med"},{"key":"4822_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2241","volume":"3","author":"LC Okell","year":"2012","unstructured":"Okell LC, Bousema T, Griffin JT, Ou\u00e9draogo AL, Ghani AC, Drakeley CJ. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun. 2012;3:1237. https:\/\/doi.org\/10.1038\/ncomms2241.","journal-title":"Nat Commun"},{"issue":"10016","key":"4822_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","volume":"387","author":"MA Penny","year":"2016","unstructured":"Penny MA, Verity R, Bever CA, et al. Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387(10016):367\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(15)00725-4.","journal-title":"Lancet"},{"issue":"5","key":"4822_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1473-3099(23)00816-2","volume":"24","author":"N Schmit","year":"2024","unstructured":"Schmit N, Topazian HM, Natama HM, et al. The public health impact and cost-effectiveness of the R21\/Matrix-M malaria vaccine: a mathematical modelling study. Lancet Infect Dis. 2024;24(5):465\u201375. https:\/\/doi.org\/10.1016\/S1473-3099(23)00816-2.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"4822_CR25","doi-asserted-by":"publisher","first-page":"e1782","DOI":"10.1016\/S2214-109X(22)00416-8","volume":"10","author":"HA Thompson","year":"2022","unstructured":"Thompson HA, Hogan AB, Walker PGT, et al. Seasonal use case for the RTS,S\/AS01 malaria vaccine: a mathematical modelling study. Lancet Glob Health. 2022;10(12):e1782\u201392. https:\/\/doi.org\/10.1016\/S2214-109X(22)00416-8.","journal-title":"Lancet Glob Health"},{"issue":"8","key":"4822_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000324","volume":"7","author":"JT Griffin","year":"2010","unstructured":"Griffin JT, Hollingsworth TD, Okell LC, et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 2010;7(8):e1000324. https:\/\/doi.org\/10.1371\/journal.pmed.1000324.","journal-title":"PLoS Med"},{"issue":"4","key":"4822_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1473-3099(15)00423-5","volume":"16","author":"JT Griffin","year":"2016","unstructured":"Griffin JT, Bhatt S, Sinka ME, et al. Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. Lancet Infect Dis. 2016;16(4):465\u201372. https:\/\/doi.org\/10.1016\/S1473-3099(15)00423-5.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"4822_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002448","volume":"14","author":"P Winskill","year":"2017","unstructured":"Winskill P, Slater HC, Griffin JT, Ghani AC, Walker PGT. The US President\u2019s Malaria Initiative, Plasmodium falciparum transmission and mortality: a modelling study. PLOS Med. 2017;14(11):e1002448. https:\/\/doi.org\/10.1371\/journal.pmed.1002448.","journal-title":"PLOS Med"},{"key":"4822_CR29","unstructured":"Charles G, Winskill P, Topazian H, et al. malariasimulation: an individual based model for malaria. 2024."},{"key":"4822_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6606","volume":"5","author":"LC Okell","year":"2014","unstructured":"Okell LC, Cairns M, Griffin JT, et al. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat Commun. 2014;5:5606. https:\/\/doi.org\/10.1038\/ncomms6606.","journal-title":"Nat Commun"},{"key":"4822_CR31","unstructured":"United Nations Department of Economic and Social Affairs Population Division. World 532 Population Prospects 2022 demographic indicators by region, subregion and country, annually for 533 1950\u20132100. 2022. https:\/\/population.un.org\/wpp\/."},{"issue":"10","key":"4822_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003359","volume":"17","author":"A Mousa","year":"2020","unstructured":"Mousa A, Al-Taiar A, Anstey NM, et al. The impact of delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: a systematic review and a pooled multicentre individual-patient meta-analysis. PLoS Med. 2020;17(10):e1003359. https:\/\/doi.org\/10.1371\/journal.pmed.1003359.","journal-title":"PLoS Med"},{"key":"4822_CR33","doi-asserted-by":"crossref","unstructured":"Funk CC, Peterson PJ, Landsfield MF, et al. A quasi-global precipitation time series for drought monitoring: U.S. Geological Survey Data Series 832. 2014. http:\/\/pubs.usgs.gov\/ds\/832\/. Accessed 31 May 2024.","DOI":"10.3133\/ds832"},{"key":"4822_CR34","unstructured":"Winskill P. umbrella: rainfall & seasonality. 2023. https:\/\/mrc-ide.github.io\/umbrella\/index.html"},{"key":"4822_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00442-X","author":"MS Datoo","year":"2022","unstructured":"Datoo MS, Natama HM, Som\u00e9 A, et al. Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial. Lancet Infect Dis. 2022. https:\/\/doi.org\/10.1016\/S1473-3099(22)00442-X.","journal-title":"Lancet Infect Dis"},{"issue":"10287","key":"4822_CR36","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo MS, Natama MH, Som\u00e9 A, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021;397(10287):1809\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(21)00943-0.","journal-title":"Lancet"},{"issue":"4","key":"4822_CR37","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4269\/ajtmh.23-0696","volume":"110","author":"KR Dobbs","year":"2024","unstructured":"Dobbs KR, Atieli HE, Valim C, Beeson JG. Previous malaria exposures and immune dysregulation: developing strategies to improve malaria vaccine efficacy in young children. Am J Trop Med Hyg. 2024;110(4):627\u201330. https:\/\/doi.org\/10.4269\/ajtmh.23-0696.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"4822_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-025-09048-6","volume":"26","author":"ED Dabira","year":"2025","unstructured":"Dabira ED, Natama HM, Jaiteh F, et al. Seasonal mass vaccination with R21\/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial. Trials. 2025;26(1):382. https:\/\/doi.org\/10.1186\/s13063-025-09048-6.","journal-title":"Trials"},{"key":"4822_CR39","unstructured":"von Seidlein L. A cluster-randomised, open-label trial to compare the impact of combined mass vaccine and drug administrations, mass drug administration, mass vaccinations, or no intervention on Plasmodium falciparum malaria transmission. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT06068530. Accessed 16 Feb 2026"},{"issue":"32","key":"4822_CR40","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1016\/j.vaccine.2005.03.019","volume":"23","author":"KA Bojang","year":"2005","unstructured":"Bojang KA, Olodude F, Pinder M, et al. <article-title update=\"added\">Safety and immunogenicty of RTS,S\/AS02A candidate malaria vaccine in Gambian children. Vaccine. 2005;23(32):4148\u201357. https:\/\/doi.org\/10.1016\/j.vaccine.2005.03.019.","journal-title":"Vaccine"},{"issue":"47","key":"4822_CR41","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1016\/j.vaccine.2020.09.069","volume":"38","author":"HA Thompson","year":"2020","unstructured":"Thompson HA, Hogan AB, Walker PGT, et al. Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S\/AS01 vaccination. Vaccine. 2020;38(47):7498\u2013507. https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.069.","journal-title":"Vaccine"},{"key":"4822_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00090-8","author":"D Maci\u00e0","year":"2025","unstructured":"Maci\u00e0 D, Pons-Salort M, Moncunill G, Doba\u00f1o C. The effect of disease transmission on time-aggregated treatment efficacy estimates: a critical analysis of factors influencing the RTS,S and R21 malaria vaccine phase 3 trials. Lancet Infect Dis. 2025. https:\/\/doi.org\/10.1016\/S1473-3099(25)00090-8.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"4822_CR43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/hec.1629","volume":"19","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, Nord E, Siebert U, et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ. 2010;19(10):1117\u201327. https:\/\/doi.org\/10.1002\/hec.1629.","journal-title":"Health Econ"},{"key":"4822_CR44","doi-asserted-by":"publisher","DOI":"10.32614\/CRAN.package.dampack","author":"F Alarid-Escudero","year":"2024","unstructured":"Alarid-Escudero F, Knowlton G, Easterly CW, Enns E. Dampack: decision-analytic modeling package. 2024. https:\/\/doi.org\/10.32614\/CRAN.package.dampack.","journal-title":"Dampack: decision-analytic modeling package"},{"issue":"5","key":"4822_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jval.2019.02.008","volume":"22","author":"F Alarid-Escudero","year":"2019","unstructured":"Alarid-Escudero F, Enns EA, Kuntz KM, Michaud TL, Jalal H. \u201cTime traveling is just too dangerous\u201d but some methods are worth revisiting: the advantages of expected loss curves over cost-effectiveness acceptability curves and frontier. Value Health. 2019;22(5):611\u20138. https:\/\/doi.org\/10.1016\/j.jval.2019.02.008.","journal-title":"Value Health"},{"issue":"1","key":"4822_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03196-7","volume":"19","author":"SP Kigozi","year":"2020","unstructured":"Kigozi SP, Kigozi RN, Epstein A, et al. Rapid shifts in the age-specific burden of malaria following successful control interventions in four regions of Uganda. Malar J. 2020;19(1):128. https:\/\/doi.org\/10.1186\/s12936-020-03196-7.","journal-title":"Malar J"},{"issue":"7","key":"4822_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040242","volume":"4","author":"JJ Aponte","year":"2007","unstructured":"Aponte JJ, Menendez C, Schellenberg D, et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 2007;4(7):e242. https:\/\/doi.org\/10.1371\/journal.pmed.0040242.","journal-title":"PLoS Med"},{"issue":"1","key":"4822_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0805-1","volume":"14","author":"P Pemberton-Ross","year":"2015","unstructured":"Pemberton-Ross P, Smith TA, Hodel EM, Kay K, Penny MA. Age-shifting in malaria incidence as a result of induced immunological deficit: a simulation study. Malar J. 2015;14(1):287. https:\/\/doi.org\/10.1186\/s12936-015-0805-1.","journal-title":"Malar J"},{"key":"4822_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1095-6","volume":"16","author":"AB Hogan","year":"2018","unstructured":"Hogan AB, Winskill P, Verity R, Griffin JT, Ghani AC. Modelling population-level impact to inform target product profiles for childhood malaria vaccines. BMC Med. 2018;16:109. https:\/\/doi.org\/10.1186\/s12916-018-1095-6.","journal-title":"BMC Med"},{"issue":"52","key":"4822_CR50","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.1016\/j.vaccine.2016.10.078","volume":"34","author":"K Hardt","year":"2016","unstructured":"Hardt K, Bonanni P, King S, et al. Vaccine strategies: optimising outcomes. Vaccine. 2016;34(52):6691\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.078.","journal-title":"Vaccine"},{"key":"4822_CR51","unstructured":"World Health Organization. Leave no one behind: guidance for planning and implementing catch-up vaccination. World Health Organization; 2021. https:\/\/www.who.int\/publications-detail-redirect\/9789240016514. Accessed 9 Aug 2023."},{"key":"4822_CR52","unstructured":"Nolen S. U.S. to end vaccine funds for poor countries. N Y Times. March 26, 2025. https:\/\/www.nytimes.com\/2025\/03\/26\/health\/usaid-cuts-gavi-bird-flu.html. Accessed 1 Apr 2025."},{"key":"4822_CR53","unstructured":"Reevaluating and realigning United States foreign aid. 2025. https:\/\/www.whitehouse.gov\/presidential-actions\/2025\/01\/reevaluating-and-realigning-united-states-foreign-aid\/. Accessed 1 Apr 2025."},{"key":"4822_CR54","unstructured":"Withdrawing the United States from the World Health Organization. 2025. https:\/\/www.whitehouse.gov\/presidential-actions\/2025\/01\/withdrawing-the-united-states-from-the-worldhealth-organization\/. Accessed 1 Apr 2025."},{"key":"4822_CR55","unstructured":"World Health Organization. Malaria progress in jeopardy amid foreign aid cuts. 2025. https:\/\/www.who.int\/news\/item\/11-04-2025-malaria-progress-in-jeopardy-amid-foreign-aid-cuts. Accessed 14 Apr 2025"},{"issue":"1","key":"4822_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12916-024-03321-2","volume":"22","author":"F Amimo","year":"2024","unstructured":"Amimo F. Malaria vaccination: hurdles to reach high-risk children. BMC Med. 2024;22(1):111. https:\/\/doi.org\/10.1186\/s12916-024-03321-2.","journal-title":"BMC Med"},{"issue":"6","key":"4822_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.899","volume":"11","author":"H Mumtaz","year":"2023","unstructured":"Mumtaz H, Nadeem A, Bilal W, et al. Acceptance, availability, and feasibility of RTS, S\/AS01 malaria vaccine: a review. Immun Inflamm Dis. 2023;11(6):e899. https:\/\/doi.org\/10.1002\/iid3.899.","journal-title":"Immun Inflamm Dis"},{"issue":"4","key":"4822_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061395","volume":"8","author":"MT White","year":"2013","unstructured":"White MT, Bejon P, Olotu A, et al. The relationship between RTS,S vaccine-induced antibodies, CD4+ T cell responses and protection against Plasmodium falciparum infection. PLoS ONE. 2013;8(4):e61395. https:\/\/doi.org\/10.1371\/journal.pone.0061395.","journal-title":"PLoS ONE"},{"issue":"12","key":"4822_CR59","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White MT, Verity R, Griffin JT, et al. Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015;15(12):1450\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(15)00239-X.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4822_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1473-3099(13)70005-7","volume":"13","author":"P Bejon","year":"2013","unstructured":"Bejon P, White MT, Olotu A, et al. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis. 2013;13(4):319\u201327. https:\/\/doi.org\/10.1016\/S1473-3099(13)70005-7.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4822_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-011316","volume":"8","author":"H Diawara","year":"2023","unstructured":"Diawara H, Bocoum FY, Dicko A, et al. Cost of introducing and delivering malaria vaccine (RTS, S\/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso. BMJ Glob Health. 2023;8(4):e011316. https:\/\/doi.org\/10.1136\/bmjgh-2022-011316.","journal-title":"BMJ Glob Health"},{"key":"4822_CR62","unstructured":"C\u00f4te d\u2019Ivoire makes history as first nation to deploy R21\/Matrix-MTM malaria vaccine | University of Oxford. 2024. https:\/\/www.ox.ac.uk\/news\/2024-07-15-c-te-d-ivoire-makes-history-first-nation-deploy-r21matrix-m-malaria-vaccine. Accessed 16 Jul 2024."},{"key":"4822_CR63","unstructured":"South Sudan launches R21 Malaria vaccine rollout to protect children. 2024. https:\/\/www.gavi.org\/news\/media-room\/south-sudan-launches-r21-malaria-vaccine-rollout-protect-children. Accessed 22 Jul 2024."},{"key":"4822_CR64","unstructured":"Serum Institute of India. Oxford R21\/Matrix-MTM malaria vaccine receives WHO recommendation for use paving the way for global roll-out. 2023. https:\/\/www.seruminstitute.com\/press_release_sii_021023.php. Accessed 14 Aug 2024."},{"key":"4822_CR65","unstructured":"Gavi, The Vaccine Alliance. Malaria vaccine market shaping roadmap. Gavi, The Vaccine Alliance; 2023. https:\/\/www.gavi.org\/sites\/default\/files\/white-paper\/WPaper_malaria-roadmap.pdf. Accessed 14 Aug 2024."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04822-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04822-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04822-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:03:49Z","timestamp":1777907029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04822-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4822"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04822-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}